News

With the increasing use of artificial intelligence and machine learning in medicine development, what role will they play in the clinical trial space moving forward?

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), shares her most important takeaways from the event including how industry is becoming more and more ready to adopt decentralized elements.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), discusses how some stakeholders view DCTs only as fully remote trials.

Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.

Recommending two enlightening books to introduce the science of thinking, learning, and doing for clinical research professionals.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, talks secure data transfer and risk mitigation.

Interim results from the lead-in cohort showed some patients who received LP-300 alongside chemotherapy experienced an average tumor size reduction of 51%.

The Phase III AALL1731 trial demonstrated that adding Blincyto (blinatumomab) to chemotherapy significantly improved three-year disease-free survival in pediatric patients with standard-risk B-cell acute lymphoblastic leukemia.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, touches on the challenges with hand-written data collection and how they can be addressed with AI.

Merck and Ridgeback Biotherapeutics have launched the Phase III MOVe-NOW trial to evaluate a new, streamlined formulation of Lagevrio (molnupiravir) for treating non-hospitalized COVID-19 patients at high risk of severe disease progression who are unable to use other antiviral therapies.

Sponsors and CROs that work with these sites can better reach marginalized communities.

Phase II Piranga trial found that the combination of xalnesiran and an immunomodulator effectively reduced hepatitis B surface antigen (HBsAg) levels, but highlighted challenges in response durability and efficacy in patients with high HBsAg levels.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, discusses how AI can be used to streamline sample collection and tracking.

Publicly funded non-inferiority trials have grown in popularity with high levels of non-inferiority margin reporting; however, a recent analysis notes a need for improved design and reporting practices to ensure clinical relevance and reliability.

Our November issue focused on patient centricity with additional coverage around data management.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights the idea of consolidating clinical technology and how it may become more popular in the future.

How cognitive evaluations can aid in meeting the growing demand for more comprehensive safety profiles.

CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses the concept of data exhaust and how managing it can be simplified with artificial intelligence.

The PANOVA-3 study met its primary endpoint, demonstrating an improvement in overall survival for patients treated with Tumor Treating Fields.

Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, talks AI and how it can automate repetitive processes.

New solution offers real-time data exchange and inventory control, ensuring sample integrity.

WINREVAIR (sotatercept-csrk) met the study’s primary endpoint of time to first morbidity or mortality event.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights how integration can simplify processes.

Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses how sites are being burdened by increasingly complex technologies.

To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.